# Safety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC)

> **NCT06904872** · PHASE2 · RECRUITING · sponsor: **Napo Therapeutics, S.p.A.** · enrollment: 18 (estimated)

## Conditions studied

- Short Bowel Syndrome
- Malabsorption Syndromes
- Short Gut Syndrome
- Post-Op Complication
- Functional Gastrointestinal Disorders

## Interventions

- **DRUG:** Crofelemer Powder for Oral Solution
- **DRUG:** Matched Placebo Powder for Oral Solution

## Key facts

- **NCT ID:** NCT06904872
- **Lead sponsor:** Napo Therapeutics, S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-29
- **Primary completion:** 2026-02
- **Final completion:** 2026-02
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06904872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06904872, "Safety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06904872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*